PharmiNews

The Directory of Pharma Companies and News

Sanofi Genzyme

Sanofi Genzyme logo
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Category: Pharmaco
Category: Pharmaco

Sanofi Genzyme News

DateNews
2017-07-21Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Se...
2017-07-10Sanofi Genzyme and Alnylam Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational ...
2017-07-07Sanofi Genzyme and Alnylam Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients wi...
2017-06-27Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Activ...
2017-06-26Sanofi Genzyme and Alnylam to Present New Clinical Trial Results at the International Society of Thrombosis and Haemosta...
2017-06-04Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Cl...
2017-05-31Sanofi Genzyme Recognizes Ninth Annual World MS Day
2017-05-22Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rh...
2017-05-02Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life--Altering Pain Daily or Multiple Times A...
2017-04-25New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy
2017-04-25New Investigational Data on Six-Year Efficacy of Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Multiple Sclerosis Patients...
2017-04-24Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection
2017-04-24Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to S...
2017-04-11More than 30 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured...
2017-04-05Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee
2017-03-28Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with...
2017-03-22Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcom...
2017-03-04Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (d...
2017-02-28Sanofi Genzyme Recognizes Rare Disease Day 2017 with Program of Events around the World
2017-02-27Sanofi And Regeneron To Present New Data On DUPIXENT® (Dupilumab) For Moderate-To-Severe Atopic Dermatitis At Upcoming M...
2017-02-14Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease
2017-02-09Sanofi Genzyme Commitment to Patients with Rare Diseases Highlighted at WORLDSymposium 2017
2017-02-01Sanofi and Regeneron Announce First Approval of KevzaraTM (sarilumab) for the Treatment of Moderately to Severely Active...
2016-12-20Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards
2016-12-08Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the E...
2016-12-05Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma
2016-11-16Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheu...
2016-11-04Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease
2016-10-06BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine® (sargramostim) for Potential Public Health Emergency
2016-10-01Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England...
2016-09-26Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
2016-09-16Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi ...
2016-09-15Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzyme’s Aubagio® (teriflunomid...
2016-07-12Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dematitis to Highlight the Physical and Psychologi...
2016-07-06Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency
2016-06-06Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS ...
2016-05-25Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis
2016-05-16Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
2016-04-18New Data Suggesting Positive Effects of Sanofi Genzyme’s Lemtrada® (alemtuzumab) on Brain Volume Loss and Retinal Nerve ...
2016-04-15More than 35 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured...
2016-04-01Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Mode...
2016-03-11Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Ad...
2016-03-03Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease
2016-03-02Actress Madeleine Stowe and Sanofi Genzyme Launch New Phase of Take Action on MS with Dynamic Webisode Series
2016-02-29Sanofi Genzyme Recognizes Rare Disease Day 2016 with Program of Events around the World
2016-02-26Sanofi Genzyme Leadership in Rare Diseases Highlighted at WORLDSymposium 2016
2016-02-02Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Asso...
2016-01-06Sanofi Genzyme Announces Recipients of Patient Advocacy Leadership (PAL) Awards
2015-10-08Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Rec...
2015-10-07New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
2015-10-05Genzyme Introduces “vs.MS,” a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better ...
2015-10-01Sanofi: Genzyme Opts into Alnylam's ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North Am...
2015-09-23More Than 50 Presentations of New Data from Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS
2015-07-29Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program
2015-07-27Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZe...
2015-06-15Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients
2015-06-04FDA Grants Breakthrough Therapy Designation for Genzyme’s Olipudase Alfa
2015-05-27Genzyme Commemorates World MS Day with Awareness and Educational Events Globally
2015-05-26Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC
2015-05-20Genzyme’s Announces Launch of Expression of Hope III Art Exhibit
2015-05-19Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdel...
2015-04-28FDA Grants Fast Track Designation to Genzyme’s Investigational Substrate Reduction Therapy for the Treatment of Fabry Di...
2015-04-23Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activit...
2015-04-21Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
2015-04-13Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN
2015-03-30Genzyme’s Cerdelga® (eliglustat) Capsules Approved in Japan
2015-03-26Genzyme Convenes Sixth Annual Gaucher Leadership Forum
2015-03-25ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy Effective in Previously Tre...
2015-02-27Genzyme Recognizes International Rare Disease Day with Global Education and Fund-Raising Events; Announces Founding Part...
2015-02-17ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Typ...
2015-02-12Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposi...
2015-02-12Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORL...
2015-02-11Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therap...
2015-01-22European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Diseas...
2014-12-03First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval
2014-11-21European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules
2014-11-18Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
1970-01-01Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblasti...
1970-01-01Emerging data from CLL10 presented at ASH suggests \u003cstrong\u003e\u003cem\u003eLevact\u003c/em\u003e\u003csup\u003e®... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.